NCT02228239View on ClinicalTrials.gov

Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Healthy
Interventions
DRUG

Esketamine

Esketamine 84 milligram (mg) \[3\*1 of spray in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

DRUG

Mirtazapine

Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.

DRUG

Placebo (Matched to Esketamine)

Placebo \[3\*1 in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

DRUG

Placebo (Matched to Mirtazapine)

Placebo capsule will be administered orally on Day 1 in one of the treatment periods.

Trial Locations (1)

Unknown

Leiden

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02228239 - Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants | Biotech Hunter | Biotech Hunter